兄弟科技(002562.SZ):擬投資25億元建一座多劑型國際化醫藥產業基地
格隆匯 1 月 18日丨兄弟科技(002562.SZ)公佈,基於浙江省海寧市對生命健康產業發展的大力支持,兄弟科技擬依託自有原料藥產業基礎、製劑項目研發與儲備基礎以及精細化管理生產優勢,計劃總投資25億元人民幣,其中固定資產投資15億元、研發等其他投資10億元,建設一座多劑型國際化醫藥產業基地,實現兄弟科技從原料藥到製劑垂直一體化發展,助力海寧市生命健康產業發展。
項目擬建成包括符合美國、歐盟、日本等國際認證要求的片劑、硬膠囊劑、軟膠囊劑、小容量注射劑、凍乾粉針、口服液等若干條生產線,同時擬規劃建設兄弟藥業研究院、公共中試平台等,並研發取得一批高附加值藥品註冊批件。項目建成後主要用於:自有品種的研發、生產與銷售;國內外藥企、研發公司等各類MAH持有人(即藥品上市許可人)CDMO業務的承接。
公司已於2021年1月16日召開第五屆董事會第五次會議,審議通過了《關於簽署國際化醫藥產業基地建設項目投資協議的議案》,上述議案尚需通過公司股東大會審議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.